Profectus Biosciences is a research and development company dedicated to harnessing the immune system to treat and prevent viral diseases and cancers through the delivery of our proprietary prime/boost vaccines and small molecules. Click here for more information on Profectus’s programs.

May 9, 2012: Profectus BioSciences, Inc. receives $5.6M grant to develop a vaccine to protect humans against infection with NIPAH/HENDRA viruses. Learn More >

May 2, 2012: Profectus BioSciences, Inc. Receives NIAID Grant to Develop a Vesicular Stomatitis Virus. Learn More >

January 4, 2012: Profectus BioSciences, Inc. announces first Human Volunteer Immunized in Clinical Trial of Profectus BioSciences’ Vesicular Stomatitis Virus-vectored HIV-1 Vaccine. Learn More >

December 19, 2011: Profectus BioSciences, Inc., The International AIDS Vaccine Initiative (IAVI) and Ichor Medical Systems announce today the start of a multicenter Phase I trial in Africa. Learn More >